Olwyn Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 30 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 161.13%
(FY 2022)
- Profit 90.02%
(FY 2022)
- Ebitda -40.00%
(FY 2022)
- Net Worth -1.02%
(FY 2022)
- Total Assets -0.02%
(FY 2022)
About Olwyn Pharma
The Corporate was formerly known as Blue Sky Medicals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pradip Handique and Dipali Borah serve as directors at the Company.
- CIN/LLPIN
U24100AS1994PTC006655
- Company No.
006655
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Sep 1994
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Kamrup, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Olwyn Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradip Handique  | Director | 25-Sep-2010 | Current |
| Dipali Borah | Director | 06-Feb-1998 | Current |
Financial Performance and Corporate Structure Insights of Olwyn Pharma.
Olwyn Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 161.13% increase. The company also saw a substantial improvement in profitability, with a 90.02% increase in profit. The company's net worth dipped by a decrease of 1.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Olwyn Pharma?
In 2022, Olwyn Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Nezone Marketing & Medical Services Private LimitedActive 25 years 1 month
Pradip Handique is a mutual person
- New Frontier Marketing And Medical Services Private LimitedActive 25 years 1 month
Pradip Handique is a mutual person
- Millennium Marketing & Medical Services Private LimitedActive 25 years 1 month
Pradip Handique is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Olwyn Pharma?
Unlock and access historical data on people associated with Olwyn Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Olwyn Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Olwyn Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
